B-cell targeted therapeutics in clinical development

Table 1 B-cell targeting biologics in clinical development

Target	Therapeutic	Format	Mechanism	Indication	Clinical stagea^a
CD20	Rituximab	Chimeric	Depletion	RA	Approved
		IgG₁	ADCC, CDC	Pemphigus	Phase 3
				AIHA	Phase 3
				ITP	Phase 3 (newly diagnosed)
				ITP	Phase 2
				Acute IPF	Phase 1/2 (with plasma exchange)
				AIR	Phase 1
	Ofatumumab	Humanized	Depletion	RA	Phase 3
		IgG₁	ADCC, CDC	RRMS	Phase 2
				RRMS	Phase 2 (subcutaneously)
	Ocrelizumab	Humanized	Depletion	RRMS	Phase 3
		IgG₁	ADCC, CDC	PPMS	Phase 3
				SLE	Phase 3
	Veltuzumab	Humanized	Depletion	RA	Phase 2
		IgG₁	ADCC, CDC	ITP	Phase 1/2
CD19	MEDI-551	Humanized	Depletion	SSc	Phase 1
		IgG₁ afucosylated	ADCC	RRMS	Phase 1
CD22	Epratuzumab	Humanized	Partial depletion	SLE	Phase 3
		IgG₁	B-cell activation
BAFF	Belimumab	Human	Ligand neutral	SLE	Approved
		IgG₁	Survival	SLE	Phase 3 (subcutaneously)
				ITP	Phase 2
				MG	Phase 2
	Tabalumab	Human	Ligand neutral	SLE	Phase 3 (subcutaneously)
IgG4			Survival	RA	Phase 2
	Blisibimod	Peptibody	Ligand neutral	SLE	Phase 3
				ITP	Phase 2/3
BAFF/APRIL	Atacicept	Receptor	Ligand neutral	SLE	Phase 2/3
		Fc fusion	Survival
CD40L	CDP7657	Pegylated	Co-stimulation	SLE	Phase 1
		Fab	Blockade
B7RP1	AMG-557	Human	Co-stimulation	SCLE	Phase 1
		IgG	Blockade	Psoriasis	Phase 1
				SLE	Phase 1
ICOS	MEDI-570	Human	Depletion	SLE	Phase 1
		IgG₁ afucosylated	ADCC
IL-21	NN8828	Humanized	Ligand neutral	RA	Phase 1
		IgG₁

ADCC, antibody-dependent cellular cytotoxicity; AIHA, autoimmune hemolytic anemia; AIR, autoimmune retinopathy; APRIL, a proliferation-inducing ligand; BAFF, B-cell activating factor; CD40L, CD40 ligand; CDC, complement-dependent cytotoxicity; IPF, idiopathic pulmonary fibrosis; ITP, idiopathic thrombocytopenia purpura; MG, myasthenia gravis; PPMS, primary progressive multiple sclerosis; RA, rheumatoid arthritis; RRMS, relapsing remitting multiple sclerosis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; SSLE, subacute cutaneous lupus erythematosus. ^aSource for clinical trial status: www.clinicaltrials.gov (as of February 2013).

ISSN: 1478-6362